Cesare Hassan

Cesare Hassan

Auto-generated profile, based on publicly available information

Cesare Hassan

IRCCS Humanitas Research Hospital, Lombardia, Italy

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2019 in Endoscopy
Verified
Journal Article
Closed access
PDF file
CHCesare Hassan
Cesare Hassan
JEJames East
James East
FRFranco Radaelli
Franco Radaelli
CSCristiano Spada
Cristiano Spada
RBRobert Benamouzig
Robert Benamouzig
JDJean-Marc Dumonceau
Jean-Marc Dumonceau
Main Recommendations: ESGE recommends a low fiber diet on the day preceding colonoscopy.Strong recommendation, moderate quality evidence.ESGE recommends the use of enhanced instructions for bowel preparation.Strong recommendation, moderate quality evidence.ESGE suggests adding oral simethicone to bowel preparation.Weak recommendation, moderate quality evidence.ESGE recommends split-dose bowel preparation for elective colonoscopy.Strong recommendation, high quality evidence.ESGE recommends, for patients undergoing afternoon colonoscopy, a same-day bowel preparation as an acceptable alternative to split dosing.Strong recommendation, high quality evidence.ESGE recommends to start the last dose of bowel preparation within 5 hours of colonoscopy, and to complete it at least 2 hours before the beginning of the procedure.Strong recommendation, moderate quality evidence.ESGE recommends the use of high volume or low volume PEG-based regimens as well as that of non-PEG-based agents that have been clinically validated for routine bowel preparation. In patients at risk for hydroelectrolyte disturbances, the choice of laxative should be individualized.Strong recommendation, moderate quality evidence.

12 September 2013 in Endoscopy
Verified
Journal Article
Closed access
PDF file
CHCesare Hassan
Cesare Hassan
EQEnrique Quintero
Enrique Quintero
JDJean-Marc Dumonceau
Jean-Marc Dumonceau
JRJaroslaw Regula
Jaroslaw Regula
CBCatarina Brandão
Catarina Brandão
DLDavid Lieberman
David Lieberman
This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was adopted to define the strength of recommendations and the quality of evidence. Main recommendations: The following recommendations for post-polypectomy endoscopic surveillance should be applied only after a high quality baseline colonoscopy with complete removal of all detected neoplastic lesions. 1 In the low risk group (patients with 1 – 2 tubular adenomas < 10 mm with low grade dysplasia), the ESGE recommends participation in existing national screening programmes 10 years after the index colonoscopy. If no screening programme is available, repetition of colonoscopy 10 years after the index colonoscopy is recommended (strong recommendation, moderate quality evidence). 2 In the high risk group (patients with adenomas with villous histology or high grade dysplasia or ≥10 mm in size, or ≥ 3 adenomas), the ESGE recommends surveillance colonoscopy 3 years after the index colonoscopy (strong recommendation, moderate quality evidence). Patients with 10 or more adenomas should be referred for genetic counselling (strong recommendation, moderate quality evidence). 3 In the high risk group, if no high risk adenomas are detected at the first surveillance examination, the ESGE suggests a 5-year interval before a second surveillance colonoscopy (weak recommendation, low quality evidence). If high risk adenomas are detected at first or subsequent surveillance examinations, a 3-year repetition of surveillance colonoscopy is recommended (strong recommendation, low quality evidence). 4 The ESGE recommends that patients with serrated polyps < 10 mm in size with no dysplasia should be classified as low risk (weak recommendation, low quality evidence). The ESGE suggests that patients with large serrated polyps (≥ 10 mm) or those with dysplasia should be classified as high risk (weak recommendation, low quality evidence). 5 The ESGE recommends that the endoscopist is responsible for providing a written recommendation for the post-polypectomy surveillance schedule (strong recommendation, low quality evidence).

1 October 2010 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
CHCesare Hassan
Cesare Hassan
PPPerry J. Pickhardt
Perry J. Pickhardt
DRDouglas K. Rex
Douglas K. Rex

15 March 2022 in Gastroenterology
Verified
Journal Article
Open access
MWMichael B. Wallace
Michael B. Wallace
PSPrateek Sharma
Prateek Sharma
PBPradeep Bhandari
Pradeep Bhandari
JEJames East
James East
GAGiulio Antonelli
Giulio Antonelli
CHCesare Hassan
Cesare Hassan
Artificial intelligence (AI) may detect colorectal polyps that have been missed due to perceptual pitfalls. By reducing such miss rate, AI may increase the detection of colorectal neoplasia leading to a higher degree of colorectal cancer (CRC) prevention. Patients undergoing CRC screening or surveillance were enrolled in 8 centers (Italy, UK, US), and randomized (1:1) to undergo 2 same-day, back-to-back colonoscopies with or without AI (deep learning computer aided diagnosis endoscopy) in 2 different arms, namely AI followed by colonoscopy without AI or vice-versa. Adenoma miss rate (AMR) was calculated as the number of histologically verified lesions detected at second colonoscopy divided by the total number of lesions detected at first and second colonoscopy. Mean number of lesions detected in the second colonoscopy and proportion of false negative subjects (no lesion at first colonoscopy and at least 1 at second) were calculated. Odds ratios (ORs) and 95% confidence intervals (CIs) were adjusted by endoscopist, age, sex, and indication for colonoscopy. Adverse events were also measured. A total of 230 subjects (116 AI first, 114 standard colonoscopy first) were included in the study analysis. AMR was 15.5% (38 of 246) and 32.4% (80 of 247) in the arm with AI and non-AI colonoscopy first, respectively (adjusted OR, 0.38; 95% CI, 0.23-0.62). In detail, AMR was lower for AI first for the ≤5 mm (15.9% vs 35.8%; OR, 0.34; 95% CI, 0.21-0.55) and nonpolypoid lesions (16.8% vs 45.8%; OR, 0.24; 95% CI, 0.13-0.43), and it was lower both in the proximal (18.3% vs 32.5%; OR, 0.46; 95% CI, 0.26-0.78) and distal colon (10.8% vs 32.1%; OR, 0.25; 95% CI, 0.11-0.57). Mean number of adenomas at second colonoscopy was lower in the AI-first group as compared with non-AI colonoscopy first (0.33 ± 0.63 vs 0.70 ± 0.97, P < .001). False negative rates were 6.8% (3 of 44 patients) and 29.6% (13 of 44) in the AI and non-AI first arms, respectively (OR, 0.17; 95% CI, 0.05-0.67). No difference in the rate of adverse events was found between the 2 groups. AI resulted in an approximately 2-fold reduction in miss rate of colorectal neoplasia, supporting AI-benefit in reducing perceptual errors for small and subtle lesions at standard colonoscopy. gov, Number: NCT03954548.

1 May 2012 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
CHCesare Hassan
Cesare Hassan
LFLorenzo Fuccio
Lorenzo Fuccio
MBMario Bruno
Mario Bruno
NPNico Pagano
Nico Pagano
CSCristiano Spada
Cristiano Spada
ARAlessandro Repici
Alessandro Repici

28 September 2007 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
CHC. Hassan
C. Hassan
AZAngelo Zullo
Angelo Zullo
VFV. DE Francesco
V. DE Francesco
EIEnzo Ierardi
Enzo Ierardi
MGM. Giustini
M. Giustini
SMS. Morini
S. Morini